Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.54 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.51 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.51 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.51 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.51 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.51 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.51 |
| ▸ | ENPEP | Q07075 | 13/20 | 0.51 |
| ▸ | TASP1 | Q9H6P5 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30578947 | 0.97 | BACE1 (0.52) | BACE1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL30477366 | 0.97 | BACE1 (0.58) | BACE1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL31614422 | 0.94 | BACE1 (0.52) | BACE1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL10590691 | 0.94 | ENPEP (0.53) | BACE1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL31346757 | 0.93 | BACE1 (0.55) | BACE1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL30512778 | 0.92 | GRIN2D (0.56) | BACE1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL30959074 | 0.91 | ENPEP (0.52) | BACE1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL31318928 | 0.91 | GRIN2D (0.55) | BACE1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL30512610 | 0.91 | BACE1 (0.55) | BACE1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL30483533 | 0.90 | GRIN2D (0.58) | BACE1GRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564202-B2 | Composition for alleviating, preventing or treating sarcopenia, containing whey protein hydrolysate as active ingredient | NEO CREMAR CO., LTD. (KR) | 2026-03-03 | — | — | US | disclosed |
| US-20220322700-A1 | COMPOSITION FOR ALLEVIATING, PREVENTING OR TREATING SARCOPENIA, CONTAINING WHEY PROTEIN HYDROLYSATE AS ACTIVE INGREDIENT | NEO CREMAR CO.,LTD (KR) | 2022-10-13 | — | — | US | disclosed |
| CN-115052612-A | Composition for reducing, preventing or treating sarcopenia comprising hydrolyzed whey protein as an active ingredient | 每日健康营养股份有限公司 | 2022-09-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12564202-B2 | Composition for alleviating, preventing or treating sarcopenia, containing whey protein hydrolysate as active ingredient | PYGM, GYS1, ERG28 | BACE1 46/4885GRIN2D 4285/4885GRIN3B 4639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.